Maxacalcitol
Chemical compound
- In general: ℞ (Prescription only)
- (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1S)-1-(3-Hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
- 103909-75-7
- 6398761
- 2784
- DB06272
- 4911262
- N2UJM5NBF6
- CHEBI:31801
- ChEMBL333950
- DTXSID4048648
- Interactive image
- C[C@@H]([C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)OCCC(C)(C)O
InChI
- InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1
- Key:DTXXSJZBSTYZKE-ZDQKKZTESA-N
Maxacalcitol (trade name Oxarol) is a vitamin D3 analog and vitamin D receptor activator (VDRA).[1] As a pharmaceutical drug, it is used as an injection to treat secondary hyperparathyroidism resulting from hemodialysis and as a topical ointment for psoriasis.[2]
It was approved for use in Japan in 2010[3] and in Taiwan in 2018.[4]
References
- ^ Mizobuchi M, Ogata H (March 2014). "Clinical uses of 22-oxacalcitriol". Current Vascular Pharmacology. 12 (2): 324–328. doi:10.2174/15701611113119990023. PMID 23713875.
- ^ "Maxacalcitol". Inxight Drugs. National Center for Advancing Translational Sciences, U.S. National Institutes of Health.
- ^ "Maxacalcitol". New Drug Approvals in Japan. Kyoto Encyclopedia of Genes and Genomes. D01098.
- ^ Fukazawa-Shinotsuka M, Saito T, Abe M, Iida S, Wang IT, Terao K, et al. (January 2022). "Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis". Drug Research. 72 (1): 23–33. doi:10.1055/a-1581-7609. PMID 34488237.
- v
- t
- e
Vitamin D receptor modulators
- Agonists: 7-Dehydrocholesterol
- 25-Hydroxyergocalciferol
- Alfacalcidol
- Calcifediol
- Calciferol
- Calcipotriol
- Calcitriol
- Cholecalciferol (vitamin D3)
- Dihydrotachysterol
- Doxercalciferol
- EB-1089
- Eldecalcitol
- Ercalcidiol
- Ercalcitriol
- Ergocalciferol (vitamin D2)
- Lithocholic acid
- Maxacalcitol
- Paricalcitol
- Tacalcitol
- Antagonists: ZK159222
- TEI-9647
- See also
- Receptor/signaling modulators
This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e